119 related articles for article (PubMed ID: 7860418)
1. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
Bhasin S; Berman N; Swerdloff RS
J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
3. FSH is produced by GnRH-deficient men and is suppressed by testosterone.
Winters SJ
J Androl; 1994; 15(3):216-9. PubMed ID: 7928662
[TBL] [Abstract][Full Text] [Related]
4. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
5. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
[TBL] [Abstract][Full Text] [Related]
6. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
8. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
[TBL] [Abstract][Full Text] [Related]
11. Testosterone effects on luteinizing hormone and follicle-stimulating hormone responses to gonadotropin-releasing hormone in the mouse.
Huang BM; Leu SF; Yang HY; Norman RL
J Androl; 2001; 22(3):507-13. PubMed ID: 11330652
[TBL] [Abstract][Full Text] [Related]
12. The effects of continuous treatment of stallions with high levels of a potent GnRH analogue.
Boyle MS; Skidmore J; Zhang J; Cox JE
J Reprod Fertil Suppl; 1991; 44():169-82. PubMed ID: 1795259
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
14. Comparative response of rams and bulls to long-term treatment with gonadotropin-releasing hormone analogs.
Jiménez-Severiano H; D'Occhio MJ; Lunstra DD; Mussard ML; Davis TL; Enright WJ; Kinder JE
Anim Reprod Sci; 2007 Apr; 98(3-4):204-24. PubMed ID: 16616998
[TBL] [Abstract][Full Text] [Related]
15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
16. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
17. Suppression of growth hormone does not affect ongoing spermatogenesis in rats.
Awoniyi CA; Veeramachaneni DN; Roberts D; Tucker KE; Chandrashekar V; Schlaff WD
J Androl; 1999; 20(1):102-8. PubMed ID: 10100480
[TBL] [Abstract][Full Text] [Related]
18. Steroidal modulation of in vitro gonadotropin secretion in prepubertal and adult male Siberian hamsters.
Pak TR; Lynch GR; Tsai PS
J Exp Zool A Comp Exp Biol; 2003 Jul; 298(1):53-9. PubMed ID: 12840839
[TBL] [Abstract][Full Text] [Related]
19. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
[TBL] [Abstract][Full Text] [Related]
20. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
Garnick MB; Campion M
Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
